NEW YORK (GenomeWeb) – Natera said its focus on penetrating the average-risk pregnancy market with its noninvasive prenatal test is paying off as its test volumes for both average- and high-risk patients both grew in the first quarter of 2016.
A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try 360Dx Premium now.
Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.